SCHEMBL559719

SCHEMBL559719

Cc1ccc2nc(-c3nc(C(=O)Nc4cccnc4)cnc3N)[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.48
ATR Q13535 7/20 0.48
MAPT P10636 4/20 0.48
POLB P06746 2/20 0.48
LMNA P02545 1/20 0.48
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
MMP8 P22894 2/20 0.47
MMP13 P45452 2/20 0.47
ALDH1A1 P00352 4/20 0.47
TP53 P04637 2/20 0.47
GFER P55789 1/20 0.47
HSD17B10 Q99714 4/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 2/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560593 0.91 MMP2 (0.58) RAB9AATRMAPTPOLBMMP2
SCHEMBL560367 0.85 POLB (0.51) RAB9AATRMAPTPOLBLMNA
SCHEMBL560846 0.80 ATR (0.55) RAB9AATRMMP2MMP9MMP8
SCHEMBL560937 0.79 ATR (0.55) RAB9AATRMAPTPOLBALDH1A1
SCHEMBL10166538 0.79 ATR (0.57) ATRMAPTPOLBMMP2MMP9
SCHEMBL560220 0.79 ATR (0.53) RAB9AATRMAPTPOLBMMP2
SCHEMBL560651 0.79 ATR (0.53) RAB9AATRLMNAMMP2MMP9
SCHEMBL560074 0.78 ATR (0.52) ATRMAPTPOLBMMP2MMP9
SCHEMBL560124 0.78 ATR (0.52) ATRMAPTPOLBMMP2MMP9
SCHEMBL560932 0.78 ATR (0.48) RAB9AATRMAPTMMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 RAB9A 3156/4885ATR 1/4885MAPT 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.